Page 1,156«..1020..1,1551,1561,1571,158..1,1701,180..»

"Mini Brains" Are Not like the Real Thing – Scientific American

Posted: January 31, 2020 at 1:41 am

The idea of scientists trying to grow brain tissue in a dish conjures up all sorts of scary mental pictures (cue the horror-movie music). But the reality of the research is quite far from that sci-fi visionand always will be, say researchers in the field. In fact, a leader in this area of research, Arnold Kriegstein of the University of California, San Francisco, says the reality does not measure up to what some scientists make it out to be.

In a paper published on January 29 in Nature, Kriegstein and his colleagues identified which genes were active in 235,000 cells extracted from 37 different organoids and compared them with 189,000 cells from normally developing brains. The organoidsat times called mini brains, to the chagrin of some scientistsare not a fully accurate representation of normal developmental processes, according to the study.

Brain organoids are made from stem cells that are transformed from one cell type to the another until they end up as neurons or other mature cells. But according to the Nature paper, they do not always fully complete this developmental process. Instead the organoids tend to end up with cells that have not fully transformed into new cell typesand they do not re-create the normal brains organizational structure. Psychiatric and neurodevelopmental conditionsincluding schizophrenia and autism, respectivelyand neurodegenerative diseases such as Alzheimers are generally specific to particular cell types and circuits.

Many of the organoid cells showed signs of metabolic stress, the study demonstrated. When the team transplanted organoid cells into mice, their identity became crisper, and they acted more like normal cells, Kriegstein says. This result suggests that the culture conditions under which such cells are grown does not match those of a normally developing brain, he adds. Cellular stress is reversible, Kriegstein says. If we can reverse it, were likely to see the identity of cells improve significantly at the same time.

Brain organoids are getting better at recapitulating the activities of small clusters of neurons, says Kriegstein, who is a professor of neurology and director of the Eli & Edythe Broad Center for Regeneration Medicine and Stem Cell Research at U.C.S.F. Scientists often make organoids from the cells of people with different medical conditions to better understand those conditions. But some scientists may have gone too far in making claims about insights they have derived from patient-specific brain organoids. Id be cautious about that, Kriegstein says. Some of those changes might reflect the abnormal gene expression of the cells and not actually reflect a true disease feature. So thats a problem for scientists to address.

A small ball of cells grown in a dish may be able to re-create some aspects of parts of the brain, but it is not intended to represent the entire brain and its complexity, several researchers have asserted. These organoids are no more sentient than brain tissue removed from a patient during an operation, one scientist has said.

Of course, models are never perfect. Although animal models have led to fundamental insights into brain development, researchers have sought out organoids, or organs-in-a-dish, precisely because of the limitations of extrapolating biological insights from another species to humans. Alzheimers has been cured hundreds of times in mice but never in us, for instance.

That said, the current models are already very useful in addressing some fundamental questions in human brain development, says Hongjun Song, a professor of neuroscience at the Perelman School of Medicine at the University of Pennsylvania, who was not involved in the new research. Using brain organoids, he adds, the Zika virus was recently shown to attack neural stem cells, causing a response that could explain why some babies exposed to Zika in utero develop unusually small brains.

Michael Nestor, a stem cell expert, who did not participate in the new study, says his own organoids are very helpful for identifying unusual activity in brain cells grown from people with autism. And he notes that they will eventually be useful for screening potential drugs.

Even though the models will always be a simplification, the organoid work remains crucial, says PaolaArlotta, chair of the department of stem cell and regenerative biology at Harvard University, who was also not involved in the Nature study. Neuropsychiatric pathologies and neurodevelopmental conditions are generally the result of a large number of genetic changes, which are too complex to be modeled in rodents, she says.

Sergiu Pasca, another leader in the field, says that the cellular stress encountered by Kriegstein and his team might actually be useful in some conditions, helping to create in a dish the kinds of conditions that lead to diseases of neurodegeneration, for instance. What I considerthe most exciting feature remains our ability to derive neural cells and glial cells in vitro, understanding their intrinsic program of maturation in a dish, says Pasca, an assistant professor at Stanford University, who was not part of the new paper.

The ability to improve cell quality when exposed to the environment of the mouse brain suggests that it may be possible to overcome some of the current limitations, Arlotta says. There is not yet a single protocol for making brain organoids in a lab, which may be for the best at this early stage of the field. Eventually, she says, scientists will optimize and standardize the conditions in which these cells are grown.

Arlotta, who is also the Golub Family Professor of Stem Cell and Regenerative Biology at Harvard, published a study last year in Nature showing that she and her colleagues canover a six-month periodmake organoids capable of reliablyincluding a diversity of cell types that are appropriate for the human cerebral cortex. She says it is crucial for organoid work to be done within an ethical framework. Arlotta is part of a federally funded team of bioethicists and scientists working together to ensure that such studies proceed ethically. The scientists educate the bioethicists on the state of the research, she says, and the ethicists inform the scientists about the implications of their work.

Nestor feels so strongly about the importance of linking science, policy and public awareness around stem cell research that he has put his own laboratory at the Hussman Institute for Autism on hold to accept a year-long science-and-technology-policyfellowship with the American Association for the Advancement of Science. He says he took the post to make sure the public and policy makers understand what they need to know about organoids and other cutting-edge science and to learn how to communicate about science with them.

One thing all of the scientists interviewed for this article agree on is that these brain organoids are not actual mini brains, and no one is trying to build a brain in a dish. Even as researchers learn to make more cell types and grow them in more realistic conditions, they will never be able to replicate the brains structure and complexity, Kriegstein says. The exquisite organization of a normal brain is critical to its function, he adds. Brains are still the most complicated structure that nature has ever created.

View post:
"Mini Brains" Are Not like the Real Thing - Scientific American

Posted in Cell Medicine | Comments Off on "Mini Brains" Are Not like the Real Thing – Scientific American

Lab-grown heart cells implanted into human patient for the first time – New Atlas

Posted: January 31, 2020 at 1:41 am

In what is a world-first and potentially the dawn of a new medical technology to treat damaged hearts, scientists in Japan have succeeded in transplanting lab-grown heart cells into a human patient for the first time ever. The procedure is part of a cutting-edge clinical trial hoped to open up new avenues in regenerative medicine, with the treatment to be given to a further nine patients over the coming years.

The clinical trial harnesses the incredible potential of induced pluripotent stem cells (IPSCs), a Nobel Prize-winning technology developed at Kyoto University in 2006. These are created by first harvesting cells from donor tissues and returning them to their immature state by exposing them to a virus. From there, they can develop into essentially any cell type in the body.

Professor Yoshiki Sawa is a cardiac surgeon at Osaka University in Japan, who has been developing a technique to turn IPSCs into sheets of 100 million heart muscle cells, which can be grafted onto the heart to promote regeneration of damaged muscles. This was first tested on pigs and was shown to improve organ function, which led Japans health ministry to conditionally approve a research plan involving human subjects.

The first transplantation of these cells is a huge milestone for the researchers, with the operation taking place earlier this month and the patient now recovering in the general ward of the hospital. The sheets are biodegradable, and once implanted on the surface of the heart are designed to release growth factors that encourage new formation of healthy vessels and boost cardiac function.

The team will continue to monitor the first patient over the coming year, and over the next three years aims to carry out the procedure on a total of 10 patients suffering from ischemic cardiomyopathy, a condition caused by a heart attack or coronary disease that has left the muscles severely weakened.

I hope that [the transplant] will become a medical technology that will save as many people as possible, as Ive seen many lives that I couldnt save, Sawa said at a news conference on Tuesday, according to The Japan Times.

Source: The Japan Times

See more here:
Lab-grown heart cells implanted into human patient for the first time - New Atlas

Posted in Cell Medicine | Comments Off on Lab-grown heart cells implanted into human patient for the first time – New Atlas

Movers and Shakers, Jan. 31 | BioSpace – BioSpace

Posted: January 31, 2020 at 1:41 am

Decibel Therapeutics Industry veteran Laurence Reid has been tapped to serve as Boston-based Decibels acting chief executive officer. Current CEO Steven Holtzman is retiring and will become a strategic business advisor to the company. Reid is an entrepreneur-in-residence at Third Rock Ventures and has held numerous leadership positions in the biotech industry. Most recently, he served as the CEO of Warp Drive Bio, a drug discovery company advancing novel oncology and anti-infective medicines, and where he ultimately negotiated the successful merger of the company with Revolution Medicines in 2018. In his previous role as chief business officer of Alnylam Pharmaceuticals, he led business development, finance and legal functions.

Passage Bio Bruce Goldsmith was named CEO of Passage Bio. He succeeds Stephen Squinto, who co-founded Passage Bio and served as interim chief executive officer since 2018. Goldsmith joins Passage Bio from Deerfield Management where he was a venture partner responsible for early-stage investments and served as interim chief executive officer of Civetta Therapeutics. Previously, Goldsmith was chief operating officer at Lycera, a company developing first-in-class small molecules for immuno-oncology and autoimmune disease. Goldsmith also held senior positions at Allos Therapeutics and GPC Biotech as well as various strategic marketing and business development roles at Johnson & Johnson focused on oncology and virology.

Century Therapeutics -- Former Novartis CEO Joseph Jimenez joined the board of directors of Century Therapeutics. Jimenez joins Centurys board with more than 20 years of experience as a senior leadership executive in the pharmaceutical and consumer products industries. He retired in 2018 as the CEO of Novartis. Also, the company tapped Celgene veteran Greg Russotti as its chief technology officer. Russotti brings more than 25 years of industrial experience in bioprocess development and implementation, including extensive knowledge in cell therapy technical operations. Most recently, he was vice president of cell therapy technical development at Celgene, where he guided CMC efforts for five different cell therapy products to IND and clinical-stage development. Before Celgene, Russotti spent 12 years at Merck Research Laboratories with roles in cell culture development, downstream purification, pilot plant operations, and manufacturing facility startup.

H.E.L. Group -- H.E.L Group announced the appointment of three new members to its senior team, who will focus primarily on strengthening production and service support for its scientific instrumentation and software. The company appointed Roy Eggleston to the newly created role of Global Quality Manager, while Tony Heywood from AB Turnkey Solutions takes over Roys previous position as Production Manager. John Forbes, formerly a senior manager at Thermo Fisher Scientific, joins as Global Service Manager.

ImageOne Medical Former U.S. Olympian Tuesday Middaugh Slomovitz was named COO of Florida-based ImageOne Medical.

Verrica Pharmaceuticals Pennsylvania-based Verrica named two new vice presidents in its commercial operations group. Gerard DiGirolamo joins as head of sales and Sheila Kennedy has been appointed head of marketing. Prior to Verrica, DiGirolamo spent over 16 years with Stiefel, currently a GSK company, in roles of increasing and varying responsibilities, spanning multiple brands within the dermatology space. Kennedy joins Verrica with over 20 years of success as a biopharmaceutical marketing strategist. In her most recent role, Kennedy directed global and U.S. marketing for the dermatology medication Rhofade. In a prior role, Kennedy served as head of marketing for Onset Dermatologics.

TELA Bio Peter Murphy was named to the newly created role of chief commercial officer. In this position, Murphy will be responsible for the companys continued strategic expansion of its commercial operations. Murphy joins TELA with more than 20 years of commercial sales and marketing. Most recently, he was head of sales at Pacira Pharmaceuticals, where he led the development, management, expansion and execution of a product sales team in the U.S.

NuHope -- Jeff Dunkel assumes the role of NuHope CEO following his position as head of strategy at TITAN SPINE.NuHope is a San Antonio-based outpatient opioid and pain treatment center focused on taper effectiveness, which specificallyreduces controlled substance use in those dependent on opioids.

ValueHealth, LLC William J. Hozack was named medical director. In this new role, Hozack will oversee ValueHealth's clinical protocols, quality outcome measures, patient care pathways, and bundled payments with warranty programs. He will also serve as a liaison to ValueHealth's Advisory Board and provide strategic guidance to the company.

Enzychem Lifesciences Liver disease specialist Michael Charlton joined the companys scientific advisory board. Charlton is currently director of the Center for Liver Diseases at University of Chicago School of Medicine. He has served as president of the International Liver Transplant Society.

Disc Medicine John Quisel was named president and CEO of Disc Medicine. Quisel joins Disc Medicine after more than a decade at Acceleron Pharma where he most recently was CBO. In this planned transition, co-founder and interim CEO Brian MacDonald, will continue to serve as a senior advisor and director of the company.

NeoImmuneTech, Inc. -- Gene Namgoong was named COO of Maryland-based NeoImmuneTech, a T cell-focused immunotherapeutics company. As COO, Namgoong will play a key role in advancing its business operations and shaping its corporate culture. Namgoong joined NeoImmuneTech in 2014 as a legal advisor, later assuming the critical role of general counsel in 2016.

SutroVax Jim Wassil was named COO of California-based SutroVax, Inc. Wassil will lead clinical development, regulatory affairs, medical affairs, quality assurance and program management activities. He spent the past three decades in positions of increasing responsibility in the vaccine divisions of Merck, Novartis, and Pfizer. Most recently, he was responsible for market access, policy, pricing, tender negotiations, epidemiology and health outcomes as the business unit lead for Pfizer Vaccines.

Insmed Incorporated -- Sara Bonstein was named CFO of New Jersey-based Insmed. Bonstein will assume responsibility for leading the company's global financial operations. She most recently served as CFO and COO of OncoSec Medical Incorporated. Prior to joining OncoSec, Bonstein served as the CFO at Advaxis, Inc.

Original post:
Movers and Shakers, Jan. 31 | BioSpace - BioSpace

Posted in Cell Medicine | Comments Off on Movers and Shakers, Jan. 31 | BioSpace – BioSpace

Hitachi Chemical Advanced Therapeutics Solutions Announces Opening of Its New Facility Designed to Manufacture Commercial Cell and Gene Therapies -…

Posted: January 31, 2020 at 1:41 am

The facility (75 Commerce) currently includes six classified environment rooms, with the capacity to add more rooms that can be specifically configured to accommodate growing client needs. The new facility includes state-of-the-art manufacturing development laboratories, quality control and microbiological laboratories, warehousing, executive offices and meeting space. The companys ongoing investment in facility expansion complements ongoing investments in the companys Quality Systems and commercial expertise, all with the aim of meeting its commitments to existing clients with near-term expectations for commercial product manufacturing.

The opening of this new facility marks an important milestone for HCATS and will offer a state-of-the-art resource for our clients as they commercialize cell and gene therapies. Access to this type of manufacturing space is needed across the industry to ensure the continued growth and momentum of these promising therapeutics, said Robert Preti, Ph.D., President and CEO, HCATS, and General Manager, RMBS. This facility will require up to 500 more employees to reach full operational capacity over the next several years, supporting our growing roster of clients.

I am excited for Hitachi Chemical Advanced Therapeutics Solutions future in New Jersey, and I have no doubt that their new, state-of-the-art facility will not only help New Jersey residents, but also contribute to expanding the innovation economy by bringing up to 500 new jobs to our state, said Governor Phil Murphy of New Jersey. With our highly educated and diverse workforce, New Jersey is the perfect location for expanding biotech firms like Hitachi Chemical.

The leadership and employees of HCATS, along with officials of Hitachi Chemical and local dignitaries, commemorated the milestone with a ribbon cutting ceremony on January 29 at the new facility. For a selection of images from the ceremony please visit https://www.pctcelltherapy.com/pct-pulse/HCATS-Opens-Second-New-Jersey-Facility

About the Hitachi Chemical Regenerative Medicine Business Sector

The Hitachi Chemicals Regenerative Medicine Business Sector provides contract development and manufacturing organization (CDMO) services at current Good Manufacturing Practices (cGMP) standards, including clinical manufacturing, commercial manufacturing, and manufacturing development. The global footprint of the business is over 200,000 square feet and includes operations in North America (Allendale, New Jersey and Mountain View, California), Europe (Munich, Germany), and Japan (Yokohama). The business leverages two decades of experience exclusively focused on the cell therapy industry.

For more information on North America services, please visit http://www.pctcelltherapy.com.

For more information on Europe services, please visit http://www.apceth.com.

For more information on Japan services, please visit http://www.hitachi-chem.co.jp/english/

View source version on businesswire.com: https://www.businesswire.com/news/home/20200130005221/en/

Read the rest here:
Hitachi Chemical Advanced Therapeutics Solutions Announces Opening of Its New Facility Designed to Manufacture Commercial Cell and Gene Therapies -...

Posted in Cell Medicine | Comments Off on Hitachi Chemical Advanced Therapeutics Solutions Announces Opening of Its New Facility Designed to Manufacture Commercial Cell and Gene Therapies -…

UAMS Professor to Present Relationships Among Food, Health, and Disease in Food Science Seminar – University of Arkansas Newswire

Posted: January 31, 2020 at 1:41 am

Photo Submitted

Dr. Mahendran Mahadevan, a professor in the Department of Obstetrics and Gynecology at the University of Arkansas for Medical Sciences, willspeakfrom 3-4 p.m. Monday, Feb.3, in Room D2 of the Food Science Building, 2650 N. Young Ave. His presentation, "Food, Health, and Disease,"is open to everyone.

Mahadevan's presentation will focus on how different types of food and beverages plays a role in human body's health defense systems (Angiogenesis, stem cells/regeneration, microbiome, DNA protection, and immunity). This basic biological knowledge related to foods will be useful for better understanding about the effects of foods on the prevention and management of human diseases.

Mahadevan's research interests include: 1) roles of genetics, obesity, nutrition, food supplements, nutraceuticals, physical activity and other environmental/life style factors on prevention/public health and maternal, fetal, and child health; 2) tissue banking; 3) embryo and stem cell culture/expansion (particularly culture medium/conditions); and 4) gene therapy and stem cell gene therapy particularly in cancer and genetic diseases.

Mahadevan received his Veterinary medicine degree in 1975 from University of Ceylon Peradeniya, Sri Lanka and his doctoral degree in Reproductive biology from Monash University, Australia in 1982. His academic experience includes faculty positions in the Department of Physiology, School of medicine at the University of Ceylon and in the Department of Obstetrics and Gynecology at the University of Arkansas for Medical Sciences.

The rest is here:
UAMS Professor to Present Relationships Among Food, Health, and Disease in Food Science Seminar - University of Arkansas Newswire

Posted in Cell Medicine | Comments Off on UAMS Professor to Present Relationships Among Food, Health, and Disease in Food Science Seminar – University of Arkansas Newswire

European Medicines Agency Validates Kite’s Marketing Authorisation Application for Company’s Second CAR T Cell Therapy – PharmiWeb.com

Posted: January 31, 2020 at 1:41 am

EUROPEAN MEDICINES AGENCY VALIDATES KITES MARKETING AUTHORISATION APPLICATION FOR COMPANYS SECOND CAR T CELL THERAPY

-- Filing for Kites Second CAR T Cell Therapy Marks Potential Expansion of Companys Cell Therapy Portfolio --

Santa Monica, Calif., 28 January, 2020 Kite, a Gilead Company (Nasdaq: GILD), today announced that the companys Marketing Authorisation Application (MAA) for KTE-X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), has been validated and is now under evaluation by the European Medicines Agency (EMA). The MAA is supported by data from the single arm, open-label, Phase 2 ZUMA-2 trial, which demonstrated an overall response rate of 93 percent, with 67 percent achieving a complete response, as assessed by an Independent Radiologic Review Committee (IRRC) following a single infusion of KTE-X19 (median follow-up 12.3 months). In the safety analysis, Grade 3 or higher cytokine release syndrome (CRS) and neurologic events were seen in 15 percent and 31 percent of patients, respectively. No Grade 5 CRS or neurologic events occurred.1 Detailed findings from this trial were recently presented during an oral session at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando. Relapse rates in mantle cell lymphoma remain overwhelmingly high and there is a significant need for new therapies that may improve patients prognosis, said Ken Takeshita, MD, Kites Global Head of Clinical Development.

KTE-X19 has been granted Priority Medicines (PRIME) designation by the EMA. KTE-X19 is investigational and not approved anywhere globally. Its efficacy and safety have not been established. More information about clinical trials with KTE-X19 is available at http://www.clinicaltrials.gov.

About MCL

MCL is a rare form of non-Hodgkin lymphoma (NHL) that arises from cells originating in the mantle zone of the lymph node and typically affects men over the age of 60.

About ZUMA-2

ZUMA-2 is a single-arm, multicentre, open-label Phase 2 study involving 74 enrolled/leukapheresed adult patients (18 years old) with MCL whose disease is refractory to or has relapsed following up to five prior lines of therapy, including anthracycline or bendamustine-containing chemotherapy, anti-CD20 monoclonal antibody therapy and the BTK inhibitors ibrutinib or acalabrutinib. The objectives of the study are to evaluate the efficacy (60 patients) and safety (68 patients) after a single infusion of KTE-X19 in this patient population. The primary endpoint for the study is objective response rate (ORR). ORR in this trial is defined as the combined rate of complete responses and partial responses as assessed by an IRRC.

January 28, 2020 Page 2

Secondary endpoints include duration of response, progression-free survival, overall survival, incidence of adverse events, incidence of anti-CD19 CAR antibodies, levels of anti-CD19 CAR T cells in blood, levels of cytokines in serum, and changes over time in the EQ-5D scale score and visual analogue scale score. The study is ongoing.

About KTE-X19

KTE-X19 is an investigational, autologous, anti-CD19 CAR T cell therapy. KTE-X19 uses the XLP manufacturing process that includes T-cell selection and lymphocyte enrichment. Lymphocyte enrichment is a necessary step in certain B-cell malignancies in which circulating lymphoblasts are a common feature.2 KTE-X19 is currently in Phase 1/2 trials in acute lymphoblastic leukaemia (ALL), mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL).

About Kite

Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercialises innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that FDA, EMA and other regulatory agencies may not approve KTE-X19 for the treatment of adult patients with relapsed or refractory MCL, and any marketing approvals, if granted, may have significant limitations on its use. There is also the possibility of unfavourable results from other ongoing and additional clinical trials involving KTE-X19. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gileads Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation to update any such forward-looking statements.

# # #

XLP is a trademark of Gilead Sciences, Inc., or its related companies.

References

_________

1. Wang ML, et al. KTE-X19, an Anti-CD19 CAR T Cell Therapy, in Patients with/Refractory Mantle Cell Lymphoma: Results of the Phase 2 ZUMA-2 Study. Abstract #754 (Oral) presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition.

2. Stroncek, D., et al 2017, Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells. Journal of Translational Medicine. 2017. Vol. 15, no. 1. DOI 10.1186/s12967-017-1160-5.

Read this article:
European Medicines Agency Validates Kite's Marketing Authorisation Application for Company's Second CAR T Cell Therapy - PharmiWeb.com

Posted in Cell Medicine | Comments Off on European Medicines Agency Validates Kite’s Marketing Authorisation Application for Company’s Second CAR T Cell Therapy – PharmiWeb.com

Preclinical Work on Red Blood Cell-Based Therapies in HPV-Positive Solid Tumors Provides Rationale for Clinical Trials in Humans – Cancer Therapy…

Posted: January 31, 2020 at 1:41 am

A new technology for producingactivated antigen carrier cells (AACs) for cancer immunotherapy was presentedby the biotechnology company SQZ Biotech at the Society for Immunotherapy ofCancer (SITC) meeting in Maryland in November 2019.1

The innovative technique uses amicrofluidics platform to introduce antigen and adjuvant to red blood cells(RBCs), which are then introduced to the patient and engulfed by antigen-presentingcells in order to generate a T-cell response. The company presented preclinicaldata at SITC, detailing the steps of the new production technique and showingdata from preliminary mouse model work.

SQZ chose to first test thetherapy on the TC-1 tumor model of human papillomavirus (HPV)-positive cancers,a common target, as the E6 and E7 HPV tumor antigens are unique to tumors andabsent on healthy cells. The preliminary data show that in mice, the engineeredAACs are briskly taken up and engulfed by macrophages and dendritic cells,resulting in clearance from the blood within 60 minutes.

When you inject the engineeredcells in mice, they get taken up very quickly within the phagocytic cellswithin the hour. We see powerful CD8 T-cell responses and CD4 T-cell responses.These CD8 responses subsequently infiltrate the tumor and drive a very strongtumor regression, said Armon Sharei, PhD, SQZ CEO and cofounder.

The team implanted a tumor cellline in mice before treating them with engineered AACs after 10 days. Analysis of the tumor-infiltratinglymphocytes in these mice showed that approximately 70% of them were specificfor the antigen introduced by the engineered AACs.

IfI read the data correctly, what they report is that in that experiment, thevast majority of the T cells in the tumor were specific for the peptide in thetumor cells. This is remarkable, as this is evidence for a very specific effect,said Christian Ottensmeier, MD, PhD, professor of experimental medicine at theUniversity of Southampton in the U.K.

The AAC treatment also increasedsurvival and reduced tumor volume in some of the tumor-engrafted mice but theresults were perhaps a little underwhelming considering the high specificity ofthe reported T-cell response.

Onlyabout 50% of the mice survived; that is less than I would have expected forsuch an impressive T-cell response, said Dr Ottensmeier. The experiments needto be expanded upon to further investigate this discrepancy. Why are the Tcells only tackling the tumor effectively in 50% of the mice?

The work is only preliminary, but several questions will be addressed in a planned clinical trial, adding to a similar, ongoing trial using peripheral blood mononuclear cells targeting HPV-positive solid tumors (ClinicalTrials.gov Identifier: NCT04084951). On January 30, 2020, SQZ announced that the first patient in its phase 1 trial of SQZ-PBMC-HPV had been dosed. It is the first trial advancing into the clinic that was part of the 2018 SQZ-Roche collaboration, which will focus on antigen-presenting cells in oncology.2

See the original post here:
Preclinical Work on Red Blood Cell-Based Therapies in HPV-Positive Solid Tumors Provides Rationale for Clinical Trials in Humans - Cancer Therapy...

Posted in Cell Medicine | Comments Off on Preclinical Work on Red Blood Cell-Based Therapies in HPV-Positive Solid Tumors Provides Rationale for Clinical Trials in Humans – Cancer Therapy…

A step closer to tailored treatment of severe rheumatic diseases – Hospital Healthcare Europe

Posted: January 31, 2020 at 1:41 am

It is simply not possible to predict which medication will work for the individual patient, and it is therefore a matter of trying the different treatment options: glucocorticoids, low dose chemotherapeutic drugs or newer biological drugs. Until now.

A new research project from Aarhus University and Aarhus University Hospital in Denmark suggest that it is the composition of cells in the joint of the individual patient which determines whether the medicine is effective or not. The researcher behind the study, published in the journal of the American College of Rheumatology (ACR Open), is medical doctor and PhD Tue Wenzel Kragstrup from the Department of Biomedicine at Aarhus University and the Department of Rheumatology at Aarhus University Hospital.

So far, weve examined the effect of nine drugs in three different in vitro models. We can see that the effect of a given drug depends on the cell compositions. This leads us to hope that the immunological cells and inflammatory signalling molecules in the joint of each individual patient will be able to predict the most effective treatment, says Tue Wenzel Kragstrup.

The studys in vitro models consist of cell cultures isolated from joint fluids aspirated from the joints of patients with severe arthritis as part of the treatment at Aarhus University Hospital. The researchers then used the diseased cells from the joint fluid to examine the effects of different types of medicine, explains Tue Wenzel Kragstrups colleague, PhD student Morten Aagaard Nielsen from the Department og Biomedicine, who is first author of the article.

As far as we know, this is the first description of a direct association between the composition of the immune system cells and the effect of medication, Morten Aagaard Nielsen says. Tue Wenzel Kragstrup adds: The findings are based on the assumption that the cells in the test tube behaving like they would behave in the patient. So of course, the research result must be validated in humans in a larger number of patients, says Tue Wenzel Kragstrup, who concurrent with his biomedical research is in rheumatology specialist training.

It was at the hospital while meeting patients racked with pain, that Tue Wenzel Kragstrup got the idea and invented the project.

Today, the first-choice drug has no effect in around one in three patients. So, doctors often have to try several different types of medicine before they find the right one. This is a process that may take years, because a drug typically takes three to four months to be effective, explains Tue Wenzel Kragstrup.

And while we wait, the patients continue to experience swelling and pain not to mention the permanent damage that can occur in the joints as a result of persistent inflammation, he says.

Tue Wenzel Kragstrup hopes that the research results in time can be translated into a simple test such as a blood test which can determine the correct medicine for the individual patient. According to Tue Wenzel Kragstrup, this type of individualised treatment could be realised within a decade.

Originally posted here:
A step closer to tailored treatment of severe rheumatic diseases - Hospital Healthcare Europe

Posted in Cell Medicine | Comments Off on A step closer to tailored treatment of severe rheumatic diseases – Hospital Healthcare Europe

Dr C. Patrick Carroll on Caution Using Opioids to Treat Sickle Cell DiseaseRelated Pain – AJMC.com Managed Markets Network

Posted: January 31, 2020 at 1:41 am

Patients had never been particularly enthusiastic about using opioids to treat their pain related to sickle cell disease, but they are more cautious now, especially as they are often meet with suspicion of addiction, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.

Patients had never been particularly enthusiastic about using opioids to treat their pain related to sickle cell disease, but they are more cautious now, especially as they are often meet with suspicion of addiction, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.

Transcript

Given the opioid epidemic, are patients who experience pain related to sickle cell disease more cautious about being prescribed and using opioids?

Well, I think first off, people were, in my experience, we're not terribly enthusiastic about taking opioids or being on opioids in the first place. So, I don't think very many people were, I don't think people were really sanguine about it before the opioid epidemic. So, in that way, things haven't changed all that much.

I think people are, patients probably are a bit more cautious. I think providers are more cautious. But there's also been, I think, a bit of an exacerbation of a standing problem, which is that people with sickle cell disease are very, are met with a great deal of suspicion of addiction. It's a condition where you can have very severe acute pain that has no objective signs, and it's treated with opioids. And so, it's kind of a setup for that. And I think that has gotten a bit worse in the past few years.

Read the original:
Dr C. Patrick Carroll on Caution Using Opioids to Treat Sickle Cell DiseaseRelated Pain - AJMC.com Managed Markets Network

Posted in Cell Medicine | Comments Off on Dr C. Patrick Carroll on Caution Using Opioids to Treat Sickle Cell DiseaseRelated Pain – AJMC.com Managed Markets Network

After a bone injury, shape-shifting cells rush to the rescue – University of Michigan News

Posted: January 29, 2020 at 5:46 pm

ANN ARBORConventional thinking is that bone regeneration is left to a small number of mighty cells called skeletal stem cells, which reside within larger groups of bone marrow stromal cells.

But new findings from the University of Michigan recasts that thinking.

In a recent study, Noriaki Ono, assistant professor at the U-M School of Dentistry, and colleagues report that mature bone marrow stromal cells metamorphosed to perform in ways similar to their bone-healing stem cell cousinsbut only after an injury.

Bone fracture is an emergency for humans and all vertebrates, so the sooner cells start the business of healing damaged boneand the more cells there are to do itthe better.

Our study shows that other cells besides skeletal stem cells can do this job as well, Ono said.

In the mouse study, inert Cxcl12 cells in bone marrow responded to post-injury cellular cues by converting into regenerative cells, much like skeletal stem cells. Normally, the main job of these Cxcl12-expressing cells, widely known as CAR cells, is to secrete cytokines, which help regulate neighboring blood cells. They were recruited for healing only after an injury.

The surprise in our study is that these cells essentially did nothing in terms of making bones, when bones grow longer, Ono said. Its only when bones are injured that these cells start rushing to repair the defect.

This is important because the remarkable regenerative potential of bones is generally attributed to rare skeletal stem cells, Ono says. These new findings raise the possibility that these mighty skeletal stem cells could be generated through the transformation of the more available mature stromal cells.

These mature stromal cells are malleable and readily available throughout life, and could potentially provide an excellent cellular source for bone and tissue regeneration, Ono says.

The study appears in the journal Nature Communications.

More information:

Read more here:
After a bone injury, shape-shifting cells rush to the rescue - University of Michigan News

Posted in Michigan Stem Cells | Comments Off on After a bone injury, shape-shifting cells rush to the rescue – University of Michigan News

Page 1,156«..1020..1,1551,1561,1571,158..1,1701,180..»